Literature DB >> 2962847

Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56268, RU-28965, erythromycin and josamycin.

G A Dette1, H Knothe, G Koulen.   

Abstract

The minimal inhibitory concentrations of macrolide antibiotics against staphylococci, streptococci and Haemophilus influenzae were determined in vitro. A-56268 was the most active and RU-28965 was the least active of the macrolides tested. The interaction at erythromycin binding sites in serum and at alpha 1-acid glycoprotein was studied. RU-28965 exhibited the highest binding affinity. The effect of binding on antimicrobial potencies was evaluated by measurements of the first-order generation rate constants and by determination of MICs of staphylococci in broth and in human serum. The activity of each of the macrolides was lowered by serum binding, but only that of RU-28965 was dramatically decreased.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2962847

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  5 in total

1.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

Review 2.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 3.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

4.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 5.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.